SUBSCRIBE
SUBSCRIBE

Lori Ellis

Head of Insights

Lori is the head of insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. She creates engaging content for clients to support their marketing objectives. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. Her experience in the television/film and audio industries benefits both BioSpace and partners through her moderation and hosting of live and virtual events. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.

Business
Investing in AI: Benefits, Regulatory Challenges
In this episode of Denatured, BioSpace’s Head of Insights Lori and guests from Teva Pharmaceuticals and TOWER Capital discuss the opportunities, regulatory challenges and uncertainty surrounding AI.
November 7, 2024
 · 
1 min read
 · 
Lori Ellis
Business
Steady But Slow: Future Outlook For Investment
In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital review the investment landscape this year and the policies influencing investment heading into 2025.
October 24, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
How AI Could Ease Tension in Clinical Trials
In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on AI and the opportunity in patient lives.
October 10, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
AI Return on Investment: Just Because We Can, Should We?
In this episode, Lori and guests continue their exploratory discussion on AI and focus on the challenges of globalization and return on investment.
September 26, 2024
 · 
1 min read
 · 
Lori Ellis
VIP Event at the Bioprocessing Summing 2024
Business
The White House, Microsoft, SAS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part Two: The Future
As technology continues to evolve, companies should have strategies that incorporate an understand of where they are now, where they want to be, and do they have the talent to get there.
September 24, 2024
 · 
6 min read
 · 
Lori Ellis
From Left to right: Lori Ellis, Sherrine Eid, Colin Zick, Nagisa Sakurai, Mike Walker, Sarah Glaven
Business
The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present
Before companies and investors look towards the future, they must first understand the opportunities and challenges AI presents to them. From the benefits included in advancing processes to cybersecurity hazards, AI innovation is a balanced scale of oppportunities and risks.
September 23, 2024
 · 
10 min read
 · 
Lori Ellis
Drug Development
AI Promises: Funding Data Literacy and Reality First
In this episode, Lori and guests discuss practical approaches regarding artificial intelligence and investor and industry confidence in its current state.
September 12, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Future-Proofing: Inclusive and Protective Patient Strategies
In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori and guests discuss framing strategies designed to protect DEI initiatives from legal challenges.
August 29, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
August 15, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Positioning QARA as a Market Access Function in Globalization
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
August 6, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
The Benefits of a Connected Quality & Regulatory Ecosystem
In this live panel discussion, speakers navigate integrated ecosystems and the future of QARA. An executive summary is available.
August 6, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Applying AI in Today’s Reality of QARA Processes
In this live panel discussion, speakers explore artificial intelligence in medtech and practical realities in QARA. An executive summary is available.
August 6, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
The Political Shape of the Future Clinical Trial Space
In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.
August 1, 2024
 · 
1 min read
 · 
Lori Ellis
Drug Development
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
This is the third episode of Denatured’s discussion on diversity, equity and inclusion. Here, our guests discuss imperatives around access and accountability.
July 18, 2024
 · 
1 min read
 · 
Lori Ellis
Lori Ellis interviews Dr. Peter Marks at DIA Global 2024
FDA
FDA CBER Director Dr. Peter Marks Discusses Industry Growth, Collaboration and Communication
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
July 8, 2024
 · 
1 min read
 · 
Lori Ellis
Load More